XMT 1107

Drug Profile

XMT 1107

Alternative Names: XMT-1107; XMT-1191

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mersana Therapeutics
  • Class Antineoplastics; Drug conjugates; Polymers
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 09 Mar 2017 Mersana Therapeutics has patent protection for Fleximer-ADC platform technology in the European Union
  • 03 Jun 2014 Mersana Therapeutics completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in the US (NCT01011972)
  • 15 May 2013 Mersana Therapeutics completes enrolment in its phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in the US (NCT01011972)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top